Literature DB >> 11011113

Absence of germline CHK2 mutations in familial gastric cancer.

K Kimura1, K Shinmura, K Yoshimura, K Shimizu, H Katai, Y Beppu, H Moriya, J Yokota.   

Abstract

Recently, the CHK2 gene was identified as being a candidate gene responsible for Li-Fraumeni syndrome (LFS). Gastric cancer is often clustered in families with LFS, so it is possible that germline CHK2 mutation is also present in familial gastric cancer (FGC). We therefore defined the genomic structure of the CHK2 gene, designed intronic primers, and searched for germline CHK2 mutations in 25 FGC cases by polymerase chain reaction-single strand conformational polymorphism analysis of the entire coding region. In all of the 25 cases, at least two siblings had histories of gastric cancer. There were no FGC cases that showed germline CHK2 mutations. Thus, it was indicated that germline CHK2 mutations do not contribute to the familial clustering of gastric cancer.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11011113      PMCID: PMC5926446          DOI: 10.1111/j.1349-7006.2000.tb01028.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  32 in total

1.  Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway.

Authors:  P Chaturvedi; W K Eng; Y Zhu; M R Mattern; R Mishra; M R Hurle; X Zhang; R S Annan; Q Lu; L F Faucette; G F Scott; X Li; S A Carr; R K Johnson; J D Winkler; B B Zhou
Journal:  Oncogene       Date:  1999-07-15       Impact factor: 9.867

2.  Moderate frequency of BRCA1 and BRCA2 germ-line mutations in Scandinavian familial breast cancer.

Authors:  S Håkansson; O Johannsson; U Johansson; G Sellberg; N Loman; A M Gerdes; E Holmberg; N Dahl; N Pandis; U Kristoffersson; H Olsson; A Borg
Journal:  Am J Hum Genet       Date:  1997-05       Impact factor: 11.025

3.  Detection of novel germ-line p53 mutations in diverse-cancer-prone families identified by selecting patients with childhood adrenocortical carcinoma.

Authors:  Y Sameshima; Y Tsunematsu; S Watanabe; T Tsukamoto; K Kawa-ha; Y Hirata; H Mizoguchi; T Sugimura; M Terada; J Yokota
Journal:  J Natl Cancer Inst       Date:  1992-05-06       Impact factor: 13.506

4.  RER phenotype and its associated mutations in familial gastric cancer.

Authors:  K Shinmura; M Tani; J Isogaki; Y Wang; H Sugimura; J Yokota
Journal:  Carcinogenesis       Date:  1998-02       Impact factor: 4.944

5.  E-cadherin germline mutations in familial gastric cancer.

Authors:  P Guilford; J Hopkins; J Harraway; M McLeod; N McLeod; P Harawira; H Taite; R Scoular; A Miller; A E Reeve
Journal:  Nature       Date:  1998-03-26       Impact factor: 49.962

6.  Family history and the risk of stomach and colorectal cancer.

Authors:  C La Vecchia; E Negri; S Franceschi; A Gentile
Journal:  Cancer       Date:  1992-07-01       Impact factor: 6.860

Review 7.  Li-Fraumeni syndrome--a molecular and clinical review.

Authors:  J M Varley; D G Evans; J M Birch
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

8.  Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome.

Authors:  J M Birch; V Blair; A M Kelsey; D G Evans; M Harris; K J Tricker; J M Varley
Journal:  Oncogene       Date:  1998-09-03       Impact factor: 9.867

9.  Identification of germ-line E-cadherin mutations in gastric cancer families of European origin.

Authors:  S A Gayther; K L Gorringe; S J Ramus; D Huntsman; F Roviello; N Grehan; J C Machado; E Pinto; R Seruca; K Halling; P MacLeod; S M Powell; C E Jackson; B A Ponder; C Caldas
Journal:  Cancer Res       Date:  1998-09-15       Impact factor: 12.701

10.  Predominantly tumor-limited expression of a mutant allele in a Japanese family carrying a germline p53 mutation.

Authors:  Y Horio; H Suzuki; R Ueda; T Koshikawa; T Sugiura; Y Ariyoshi; K Shimokata; T Takahashi; T Takahashi
Journal:  Oncogene       Date:  1994-04       Impact factor: 9.867

View more
  5 in total

1.  The risk of gastric cancer in carriers of CHEK2 mutations.

Authors:  Urszula Teodorczyk; Cezary Cybulski; Dominika Wokołorczyk; Anna Jakubowska; Teresa Starzyńska; Małgorzata Lawniczak; Paweł Domagała; Katarzyna Ferenc; Krzysztof Marlicz; Zbigniew Banaszkiewicz; Rafał Wiśniowski; Steven A Narod; Jan Lubiński
Journal:  Fam Cancer       Date:  2013-09       Impact factor: 2.375

2.  The CHEK2(*)1100delC mutation has no major contribution in oesophageal carcinogenesis.

Authors:  L B Koppert; M Schutte; M Abbou; H W Tilanus; W N M Dinjens
Journal:  Br J Cancer       Date:  2004-02-23       Impact factor: 7.640

3.  Establishment of cell lines with high- and low-metastatic potential from PC-14 human lung adenocarcinoma.

Authors:  N Shindo-Okada; K Takeuchi; Y Nagamachi
Journal:  Jpn J Cancer Res       Date:  2001-02

4.  Establishment of cell lines with high and low metastatic potential from A549 human lung adenocarcinoma.

Authors:  Nobuko Shindo-Okada; Kaori Takeuchi; Beom-Seok Han; Yasuhiro Nagamachi
Journal:  Jpn J Cancer Res       Date:  2002-01

Review 5.  Hereditary diffuse gastric cancer: association with lobular breast cancer.

Authors:  Kasmintan A Schrader; Serena Masciari; Niki Boyd; Sara Wiyrick; Pardeep Kaurah; Janine Senz; Wylie Burke; Henry T Lynch; Judy E Garber; David G Huntsman
Journal:  Fam Cancer       Date:  2008       Impact factor: 2.375

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.